Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
Decision brief
Answer first · skim in under a minute
This plan frames a Sanofi pipeline pdf-style news brief around 2026 clinical catalysts, with Dupixent as the anchor asset and Lantus as a mature revenue base. It also clarifies the Sanofi Pasteur MSD joint venture structure and why the pipeline matters for analysts and BD teams.
This Sanofi pipeline pdf-style update links Q1 2026 commercial numbers to near-term catalysts. Dupixent sales hit €4.17 billion (+30.8%), Lantus contributed €419 million, and Sanofi listed multiple 2026 immunology and vaccine regulatory decisions.
Contents10 sections
Key Takeaways
- Q1 2026 sales rose 13.6% at constant exchange rates; business EPS was €1.88 (+14.0% CER).
- Dupixent: €4,170 million sales (+30.8%); Lantus: €419 million (−0.7%).
- Five immunology regulatory approvals reported in the quarter.
- 2026 watch list includes Dupixent LSC (U.S.), Dupixent BP (EU), and other filings named in results appendices.
What belongs in a Sanofi pipeline pdf brief?
Investors treat Sanofi’s quarterly pack as a living Sanofi pipeline pdf. The useful core is the sales table, the Phase 3 readout list, and the regulatory calendar—not a logo slide.
For Q1 2026, Dupixent still carries growth. Legacy diabetes brands such as Lantus hold a smaller, mature base.
How is Dupixent performing as the anchor asset?
Dupixent sales were €4,170 million in Q1 2026, up 30.8% year over year. U.S. sales reached €3,023 million, a 35.9% increase that Sanofi linked to volume growth across the expanding set of approved indications.
The same release said Sanofi obtained five regulatory approvals in immunology during the quarter. That keeps Dupixent central to both revenue and pipeline news flow.
Primary source: Sanofi Q1 2026 press release (SEC Exhibit).
Where does Lantus fit in 2026?
Lantus is not a growth catalyst. It is the mature insulin glargine franchise inside the diabetes book. Q1 2026 Lantus sales were €419 million, down 0.7%.
U.S. Lantus sales were €183 million (+4.1%). Sanofi said windfall effects from competitor shortages should fade through 2026. Toujeo, by contrast, rose 10.5% to €375 million in the same table.
Which 2026 catalysts sit next to Dupixent?
Results materials and appendices list near-term regulatory decisions that business-development and competitive-intelligence teams track alongside Dupixent label expansion:
- Dupixent lichen simplex chronicus (U.S.)
- Dupixent bullous pemphigoid (EU)
- Positive Phase 3 readout: venglustat in GD3 (primary endpoint met)
- Phase 3 start: frexalimab in kidney transplant (FREXERA)
Dupixent U.S. label context: openFDA Dupixent label.
Clinical trial example in the immunology stack
One active registry entry often linked to Dupixent pruritus work is NCT05263206 in chronic pruritus of unknown origin. Teams should confirm status on ClinicalTrials.gov before citing enrollment claims.
Sanofi also reiterated full-year 2026 financial guidance: high single-digit sales growth at constant exchange rates, with business earnings per share expected to grow slightly faster than sales before share-buyback effects.
What remains unproven
A Sanofi pipeline pdf does not prove approval of every listed catalyst. Pending decisions can slip. Lantus decline rates can change with pricing and supply.
Do not treat competitor market-share claims as Sanofi-reported facts unless they appear in the SEC exhibit.
Related NovaPharma coverage
Frequently Asked Questions
What does a Sanofi pipeline pdf update usually cover?
A Sanofi pipeline pdf-style brief ties quarterly sales to late-stage catalysts. For Q1 2026, that means Dupixent growth, Lantus as a mature diabetes franchise, immunology approvals, and listed 2026 regulatory decisions.
How large were Dupixent and Lantus sales in Q1 2026?
Sanofi reported Dupixent sales of €4,170 million, up 30.8%, and Lantus sales of €419 million, down 0.7%, in its Q1 2026 results materials filed with the SEC.
Is Dupixent FDA-approved?
Yes. Dupixent (dupilumab) has multiple FDA-approved indications, including atopic dermatitis and asthma. OpenFDA label records list the current U.S. indication set.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Dupixent.
Unlock full calendar →Sanofi B.V. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
